^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • Tasigna (nilotinib) • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (IMGN151-1001) (NCT05527184)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/11/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    FOLR1
    |
    opugotamig olatansine (IMGN-151)
    Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY007) (NCT02713386)
    Phase 1/2
    NRG Oncology
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/14/2016
    Primary completion :
    09/30/2021
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • BRCA • CRP
    |
    carboplatin • paclitaxel • Jakafi (ruxolitinib)
    Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NRG-GY003) (NCT02498600)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/29/2015
    Primary completion :
    09/05/2018
    Completion :
    12/31/2025
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)
    Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/25/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Lynparza (olaparib) • Koselugo (selumetinib)
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03113487)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/01/2018
    Primary completion :
    08/26/2022
    Completion :
    06/03/2025
    PD-L1 • TP53 • MUC16
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer (NCT05672095)
    Phase 1/2
    City of Hope Medical Center
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/18/2025
    Primary completion :
    11/27/2026
    Completion :
    11/27/2026
    BRCA
    |
    BRCA wild-type
    |
    Zejula (niraparib)
    CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (NCT06690775)
    Phase 2
    TORL Biotherapeutics, LLC
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/20/2024
    Primary completion :
    10/01/2027
    Completion :
    12/01/2027
    CLDN6 • PROC
    |
    TORL-1-23 • Neulasta (pegfilgrastim)
    An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (NCT05887609)
    Phase 2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/03/2023
    Primary completion :
    04/15/2026
    Completion :
    12/01/2027
    BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)
    Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (NCT03968406)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    09/26/2019
    Primary completion :
    10/01/2027
    Completion :
    10/01/2027
    RAD51
    |
    Talzenna (talazoparib)
    Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCI-2018-00438) (NCT03552471)
    Phase 1
    Ohio State University Comprehensive Cancer Center
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    07/12/2018
    Primary completion :
    06/24/2022
    Completion :
    12/19/2022
    BRCA
    |
    BRCA mutation
    |
    Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)
    Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (NCT04415944)
    Phase 2
    Wake Forest University Health Sciences
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/20/2021
    Primary completion :
    05/31/2025
    Completion :
    07/01/2025
    MUC16
    |
    carboplatin
    Prospective Cohort Study of Germline Variant Carriers with BRCA1 or BRCA2 (NCT03296826)
    Phase N/A
    Translational Research Center for Medical Innov...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    11/08/2017
    Primary completion :
    03/31/2032
    Completion :
    03/31/2032
    BRCA1 • BRCA2 • BRCA
    Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (SL03-OHD-105) (NCT05483933)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/18/2022
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    FOLR1
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NRG-GY023) (NCT04739800)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/10/2021
    Primary completion :
    01/26/2023
    Completion :
    06/14/2025
    PD-L1 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (NCT05200260)
    Phase 2
    Shanghai Gynecologic Oncology Group
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/13/2022
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    HRD • BRCA
    |
    HRD
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)
    Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    11/15/2016
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    MUC16
    |
    Avastin (bevacizumab)
    Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer (NRG-GY027) (NCT05276973)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/08/2022
    Primary completion :
    01/30/2025
    Completion :
    01/30/2025
    PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1
    |
    HRD
    |
    carboplatin • paclitaxel • ipatasertib (RG7440)
    Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE) (NCT05920798)
    Phase 1/2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/28/2023
    Primary completion :
    07/15/2027
    Completion :
    07/15/2027
    MUC16
    |
    Keytruda (pembrolizumab)
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (NCT01081262)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/12/2010
    Primary completion :
    02/25/2015
    Completion :
    03/01/2025
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (NCT05691504)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/14/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    BRAF • BCL2L1
    |
    Cotellic (cobimetinib) • pelcitoclax (APG-1252)
    Study of AVZO-021 in Patients with Advanced Solid Tumors (ARTS-021-1001) (NCT05867251)
    Phase 1/2
    Avenzo Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/30/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2030
    HER-2 • CCNE1
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021
    Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NRG-GY021) (NCT04034927)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/04/2019
    Primary completion :
    07/31/2021
    Completion :
    09/18/2025
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imjudo (tremelimumab-actl)
    Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY004) (NCT02446600)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    03/28/2016
    Primary completion :
    02/23/2020
    Completion :
    08/23/2025
    BRCA1 • BRCA2 • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)
    Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (NCT05114421)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    11/09/2021
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    CD4
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    05/23/2016
    Primary completion :
    07/07/2022
    Completion :
    08/09/2025
    BRCA1 • BRCA2 • HRD • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (SL03-OHD-101) (NCT04406623)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    06/29/2020
    Primary completion :
    02/02/2023
    Completion :
    02/02/2023
    HRD
    |
    HRD
    |
    SL-172154
    Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (EFFORT) (NCT03579316)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/07/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HRD • BRCA
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)
    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer (NCT05456685)
    Phase 2
    AbbVie
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/28/2022
    Primary completion :
    05/12/2026
    Completion :
    05/12/2026
    FOLR1 • BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    Genomic BRCA and Extensive ovArian Cancer Testing (GREAT) (NCT04027868)
    Phase N/A
    ARCAGY/ GINECO GROUP
    Completed
    Last update posted :
    01/27/2025
    Initiation :
    12/06/2019
    Primary completion :
    11/07/2022
    Completion :
    11/07/2022
    BRCA
    Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (BAROCCO) (NCT03314740)
    Phase 2
    Mario Negri Institute for Pharmacological Research
    Completed
    Last update posted :
    01/10/2025
    Initiation :
    06/12/2017
    Primary completion :
    04/01/2021
    Completion :
    04/01/2021
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • paclitaxel • Recentin (cediranib)
    Surgery for Ovarian Cancer After PARPi Therapy in Precision (NCT06602063)
    Phase 1/2
    Shanghai Gynecologic Oncology Group
    Not yet recruiting
    Last update posted :
    11/28/2024
    Initiation :
    01/01/2025
    Primary completion :
    09/01/2029
    Completion :
    09/01/2029
    PD-L1
    |
    Tyvyt (sintilimab)
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (NCT03355976)
    Phase 2
    Brown University
    Active, not recruiting
    Last update posted :
    11/25/2024
    Initiation :
    04/30/2018
    Primary completion :
    03/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (CA116-001) (NCT05613088)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/01/2023
    Primary completion :
    06/05/2024
    Completion :
    10/11/2026
    FOLR1
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)
    Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (NCT02953457)
    Phase 2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    11/19/2024
    Initiation :
    06/29/2017
    Primary completion :
    09/15/2021
    Completion :
    08/15/2024
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448)
    Phase 1
    University of Washington
    Recruiting
    Last update posted :
    11/08/2024
    Initiation :
    10/18/2021
    Primary completion :
    12/31/2025
    Completion :
    03/30/2026
    HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    10/31/2024
    Initiation :
    04/14/2010
    Primary completion :
    10/31/2018
    Completion :
    02/13/2025
    BRCA • MUC16
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/30/2024
    Initiation :
    11/10/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    BRCA
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)
    Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (NRG-GY036) (NCT06580314)
    Phase 3
    NRG Oncology
    Not yet recruiting
    Last update posted :
    08/30/2024
    Initiation :
    01/16/2025
    Primary completion :
    12/31/2034
    Completion :
    12/31/2035
    BRCA
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Aybintio (bevacizumab biosimilar) • Avzivi (bevacizumab-tnjn)
    Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (KEYNOTE PN409) (NCT02606305)
    Phase 1/2
    ImmunoGen, Inc.
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    03/02/2016
    Primary completion :
    03/12/2021
    Completion :
    03/12/2021
    FOLR1
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)